The CD14 Knockout 769-P Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population targeting CD14 in the human 769-P renal cell carcinoma line. This product comprises a heterogeneous pool of cells with CRISPR/Cas9-mediated gene disruption, providing a loss-of-function model for studying CD14 functions in innate immunity and cancer. The polyclonal format enables population-level analyses without clonal bias, suitable for signaling and cytokine assays.
The 769-P cell line is a model of clear cell renal cell carcinoma (ccRCC), derived from a primary tumor of a 63-year-old female. It retains characteristic ccRCC features, including dysregulated hypoxia signaling, making it a relevant system for investigating tumor-intrinsic immune signaling. The CD14 knockout in this background allows dissection of innate immune contributions to renal carcinoma biology.
CD14 serves as a co-receptor for bacterial lipopolysaccharide (LPS). It binds LPS and transfers it to the TLR4/MD-2 complex, initiating MyD88-dependent signaling that activates NF-kB and MAPK pathways. Key upstream regulators include LPS-binding protein (LBP), IL-1??, and TNF. The TLR4 complex engages IRAKs and TRAF6, leading to activation of NF-kB and MAPKs (ERK, JNK, p38), which drive transcription of pro-inflammatory cytokines such as TNF, IL-6, and IL-1??. CD14 is thus a critical node in TLR4-mediated innate immune responses and cytokine production.
In ccRCC, CD14-mediated signaling may modulate the tumor inflammatory microenvironment. This knockout model enables study of how CD14 loss impacts LPS-induced NF-kB and MAPK activation, cytokine secretion, and inflammatory gene expression in renal carcinoma. Researchers can dissect CD14-dependent pathways and evaluate crosstalk between innate immunity and oncogenic processes, potentially identifying therapeutic targets for inflammation-driven cancer progression.
Applications include examining LPS-induced signaling in renal cancer, studying innate immune crosstalk in tumors, validating CD14 as a target for sepsis and sterile inflammation, and investigating inflammatory gene regulation. Representative assays are Western blotting for signaling phosphoproteins, NF-kB luciferase reporter assay, ELISA and multiplex profiling for cytokines (TNF, IL-6, IL-1??), RT-qPCR, immunofluorescence, and flow cytometry. This polyclonal knockout population is a valuable tool for immunology, cancer, and drug discovery research. For further details or ordering, please contact Ascent Research.
